Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats

A sizable proportion of hemophilia inhibitor patients fails immune tolerance induction and requires bypass agents for long-term bleed management. Recombinant human-activated coagulation Factor VII (rhFVIIa) is an on-demand bypass hemostatic agent for bleeds in hemophilia inhibitor patients. Prophyla...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Zintner, Shannon M., Small, Juliana C., Pavani, Giulia, Dankner, Lynn, Marcos-Contreras, Oscar A., Gimotty, Phyllis A., Kjelgaard-Hansen, Mads, Wiinberg, Bo, Margaritis, Paris
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Gene Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6373746/
https://ncbi.nlm.nih.gov/pubmed/30705032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018027219
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados